抗CD19嵌合抗原受体T细胞疗法治疗B细胞淋巴瘤：现状与未来方向
Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions.
作者信息
Chavez Julio C, Yassine Farah, Sandoval-Sus Jose, Kharfan-Dabaja Mohamed A
机构信息
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Division of Hematology-Oncology & Blood & Marrow Transplantation & Cellular Therapies Program, Jacksonville, FL 32224, USA.
出版信息
Int J Hematol Oncol. 2021 Aug 3;10(2):IJH33. doi: 10.2217/ijh-2020-0021. eCollection 2021 Jun.
Abstract
AIMS
To review recent data and relevant of the role of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin lymphoma (NHL).
METHODS
Review and compilation of the most recent and relevant data published in full text and abstract forms of anti-CD19 CAR T-cell therapy for B-cell NHL.
RESULTS
Different anti-CD19 CAR T-cell therapy products have been tested and shown significant clinical activity across B-cell NHL patients. The objective responses in relapsed DLBCL, FL and MCL were 50-83%, 83-93% and 93%, respectively.
CONCLUSIONS
Anti-CD19 CAR T-cell therapy is a viable option for poor risk refractory B-cell NHLs.
摘要
目的
回顾近期关于抗CD19嵌合抗原受体（CAR）T细胞疗法在B细胞非霍奇金淋巴瘤（NHL）中作用的数据及相关内容。
方法
回顾并汇编以全文和摘要形式发表的关于抗CD19 CAR T细胞疗法治疗B细胞NHL的最新及相关数据。
结果
已对不同的抗CD19 CAR T细胞疗法产品进行测试，结果显示其在B细胞NHL患者中具有显著的临床活性。复发弥漫性大B细胞淋巴瘤（DLBCL）、滤泡性淋巴瘤（FL）和套细胞淋巴瘤（MCL）的客观缓解率分别为50% - 83%、83% - 93%和93%。
结论
抗CD19 CAR T细胞疗法是高危难治性B细胞NHL的一种可行选择。
相似文献
1
Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions.抗CD19嵌合抗原受体T细胞疗法治疗B细胞淋巴瘤：现状与未来方向
Int J Hematol Oncol. 2021 Aug 3;10(2):IJH33. doi: 10.2217/ijh-2020-0021. eCollection 2021 Jun.
2
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.用于治疗复发或难治性B细胞非霍奇金淋巴瘤的CD19嵌合抗原受体（CD19 CAR）重定向过继性T细胞免疫疗法。
Am J Cancer Res. 2016 Jan 15;6(2):403-24. eCollection 2016.
3
Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.抗CD19嵌合抗原受体T细胞联合纳武单抗治疗复发/难治性B细胞非霍奇金淋巴瘤安全有效。
Front Oncol. 2019 Aug 19;9:767. doi: 10.3389/fonc.2019.00767. eCollection 2019.
4
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.嵌合抗原受体T细胞疗法治疗B细胞非霍奇金淋巴瘤的进展
Biomark Res. 2021 Jul 13;9(1):58. doi: 10.1186/s40364-021-00309-5.
5
CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm.嵌合抗原受体T细胞疗法治疗非霍奇金淋巴瘤：一种新的治疗模式。
Adv Cell Gene Ther. 2019 Jul;2(3). doi: 10.1002/acg2.54. Epub 2019 Mar 28.
6
Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.嵌合受体抗 CD19 或抗 CD38 联合利妥昔单抗的 T 细胞免疫治疗对 B 细胞非霍奇金淋巴瘤的协同和持续作用。
Br J Haematol. 2010 Oct;151(1):37-46. doi: 10.1111/j.1365-2141.2010.08297.x. Epub 2010 Jul 30.
7
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.依鲁替尼可提高难治性非霍奇金淋巴瘤患者抗 CD19-CAR T 细胞疗法的疗效。
Cancer Sci. 2021 Jul;112(7):2642-2651. doi: 10.1111/cas.14915. Epub 2021 May 10.
8
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.自体移植后复发/难治性侵袭性 B 细胞淋巴瘤患者的 CD19/CD22 嵌合抗原受体 T 细胞鸡尾酒疗法。
Transplant Cell Ther. 2021 Nov;27(11):910.e1-910.e11. doi: 10.1016/j.jtct.2021.08.012. Epub 2021 Aug 20.
9
Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.嵌合抗原受体T细胞疗法治疗B细胞非霍奇金淋巴瘤：机遇与挑战
Drugs Context. 2019 Feb 13;8:212567. doi: 10.7573/dic.212567. eCollection 2019.
10
Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?复发/难治性非霍奇金淋巴瘤：工程化T细胞以表达嵌合抗原受体（CARs），一种挽救疗法？
Cureus. 2021 Jul 10;13(7):e16307. doi: 10.7759/cureus.16307. eCollection 2021 Jul.
引用本文的文献
1
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.双特异性 CAR-T 细胞靶向治疗复发或难治性 B 细胞非霍奇金淋巴瘤患者：一项 I/II 期试验。
Blood Cancer J. 2024 Aug 7;14(1):130. doi: 10.1038/s41408-024-01105-8.
2
Cancer cell targeting by CAR-T cells: A matter of stemness.嵌合抗原受体T细胞（CAR-T细胞）对癌细胞的靶向作用：干性问题。
Front Mol Med. 2022 Dec 13;2:1055028. doi: 10.3389/fmmed.2022.1055028. eCollection 2022.
3
Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy.免疫正电子发射断层扫描/单光子发射计算机断层扫描在嵌合抗原受体T细胞疗法中的当前及潜在作用。
Front Med (Lausanne). 2023 Jun 27;10:1199146. doi: 10.3389/fmed.2023.1199146. eCollection 2023.
4
T Cell Based Immunotherapy for Cancer: Approaches and Strategies.基于T细胞的癌症免疫疗法：方法与策略
Vaccines (Basel). 2023 Apr 13;11(4):835. doi: 10.3390/vaccines11040835.
5
Cellular Therapies in Chronic Lymphocytic Leukemia and Richter's Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant.慢性淋巴细胞白血病和里氏转化中的细胞疗法：嵌合抗原受体T细胞、自然杀伤细胞和异基因干细胞移植的最新进展
Cancers (Basel). 2023 Mar 18;15(6):1838. doi: 10.3390/cancers15061838.
6
The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.帕洛昔单抗维地布汀联合利妥昔单抗治疗弥漫性大 B 细胞淋巴瘤的分子基础。
Br J Haematol. 2022 Oct;199(2):245-255. doi: 10.1111/bjh.18341. Epub 2022 Jun 28.
7
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies.抗CD19和抗BCMA嵌合抗原受体T细胞的耐药性：最新进展与应对策略。
Transl Oncol. 2022 Aug;22:101459. doi: 10.1016/j.tranon.2022.101459. Epub 2022 May 23.
8
Improving CAR T-Cell Persistence.提高 CAR T 细胞持久性。
Int J Mol Sci. 2021 Oct 7;22(19):10828. doi: 10.3390/ijms221910828.
本文引用的文献
1
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
2
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.商业性抗 CD19 CAR T 细胞疗法治疗欧洲中心复发/难治性侵袭性 B 细胞淋巴瘤患者。
Am J Hematol. 2020 Nov;95(11):1324-1333. doi: 10.1002/ajh.25951. Epub 2020 Aug 25.
3
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.阿基卡宾赛妥昔单抗在非临床试验环境下的疗效、耐药性和毒性的结果和相关性。
J Clin Oncol. 2020 Sep 20;38(27):3095-3106. doi: 10.1200/JCO.19.02103. Epub 2020 Jul 15.
4
Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.开放标签、2 期研究：blinatumomab 二线治疗复发/难治侵袭性 B 细胞非霍奇金淋巴瘤。
Leuk Lymphoma. 2020 Sep;61(9):2103-2112. doi: 10.1080/10428194.2020.1759055. Epub 2020 Jun 16.
5
Value and affordability of CAR T-cell therapy in the United States.美国嵌合抗原受体T细胞疗法的价值与可及性
Bone Marrow Transplant. 2020 Sep;55(9):1706-1715. doi: 10.1038/s41409-020-0956-8. Epub 2020 May 30.
6
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.泽布替尼治疗复发/难治性套细胞淋巴瘤患者的疗效：一种选择性布鲁顿酪氨酸激酶抑制剂。
Clin Cancer Res. 2020 Aug 15;26(16):4216-4224. doi: 10.1158/1078-0432.CCR-19-3703. Epub 2020 May 27.
7
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.阿基仑赛用于复发或难治性大 B 细胞淋巴瘤的标准治疗：来自美国淋巴瘤嵌合抗原受体 T 细胞治疗联盟的结果。
J Clin Oncol. 2020 Sep 20;38(27):3119-3128. doi: 10.1200/JCO.19.02104. Epub 2020 May 13.
8
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.KTE-X19 嵌合抗原受体 T 细胞疗法治疗复发或难治性套细胞淋巴瘤。
N Engl J Med. 2020 Apr 2;382(14):1331-1342. doi: 10.1056/NEJMoa1914347.
9
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.嵌合抗原受体（CAR）T 细胞治疗后复发/难治性非霍奇金淋巴瘤采用挽救性放疗的早期经验。
Br J Haematol. 2020 Jul;190(1):45-51. doi: 10.1111/bjh.16541. Epub 2020 Mar 5.
10
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
Zotero 插件